Benzinga · Mar 5, 2026
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
TC
NASDAQ · TCRX
TScan Therapeutics, Inc.
Healthcare · Biotechnology
$0.77
Down-$0.00 (-0.39%)
Updated Aug 13, 2026, 6:54 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 61.01M
- P/E ratio
- -1.02
- Dividend yield
- 0.00%
- 52-week range
- $0.72 – $1.47
- Volume
- 527.57K
- Avg. volume
- 792.82K
Price performance
TCRX price history
1M range · 21 trading sessions · Daily adjusted prices
TCRX closed at $0.77 after 21 trading sessions, down 16.26% for the selected period.
- Last close
- $0.77
- Period change
- -16.26%
- Period low
- $0.72
- Period high
- $0.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $0.791 | $0.791 | $0.7512 | $0.773 | 527.57K |
| Aug 11, 2026 | $0.7719 | $0.7988 | $0.7636 | $0.7768 | 248.09K |
| Aug 10, 2026 | $0.7999 | $0.7999 | $0.7624 | $0.767 | 464.27K |
| Aug 7, 2026 | $0.7542 | $0.8041 | $0.7542 | $0.7962 | 336.33K |
| Aug 6, 2026 | $0.7709 | $0.7809 | $0.75 | $0.7632 | 129.86K |
| Aug 5, 2026 | $0.7448 | $0.78 | $0.7448 | $0.78 | 298.72K |
| Aug 4, 2026 | $0.716 | $0.7575 | $0.716 | $0.7365 | 796.35K |
| Aug 3, 2026 | $0.7591 | $0.7798 | $0.7201 | $0.7234 | 441.44K |
| Jul 31, 2026 | $0.78 | $0.78 | $0.7301 | $0.743 | 253.9K |
| Jul 30, 2026 | $0.756 | $0.7794 | $0.74 | $0.7557 | 430.28K |
| Jul 29, 2026 | $0.775 | $0.7978 | $0.733 | $0.7416 | 609.53K |
| Jul 28, 2026 | $0.765 | $0.7741 | $0.732 | $0.774 | 717.3K |
| Jul 27, 2026 | $0.8085 | $0.8699 | $0.7602 | $0.7683 | 907.07K |
| Jul 24, 2026 | $0.8697 | $0.892 | $0.7904 | $0.794 | 1.06M |
| Jul 23, 2026 | $0.88 | $0.9221 | $0.8464 | $0.8464 | 1.08M |
| Jul 22, 2026 | $0.94 | $0.9568 | $0.8997 | $0.8997 | 496.59K |
| Jul 21, 2026 | $0.9246 | $0.9498 | $0.9078 | $0.9404 | 145.79K |
| Jul 20, 2026 | $0.9369 | $0.97 | $0.8897 | $0.9246 | 299.5K |
| Jul 17, 2026 | $0.89 | $0.9346 | $0.876 | $0.9148 | 143.98K |
| Jul 16, 2026 | $0.913 | $0.97 | $0.8764 | $0.8986 | 651.7K |
| Jul 15, 2026 | $0.94 | $0.974 | $0.905 | $0.9231 | 473.76K |
Latest TCRX news
The latest Smart Investors Daily articles mentioning TCRX.
Stock researchCompany · Overview
TCRX research
Overview
Company profile and research snapshot.
Company profile
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 23, 2026 | Wedbush | Outperform | — |
| Jun 23, 2026 | Needham | Buy | — |
| Mar 5, 2026 | Wedbush | Outperform | — |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Earnings Breakdown: TScan Therapeutics Q4
Benzinga · Mar 4, 2026
TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027
Benzinga · Mar 4, 2026
TScan Therapeutics Q4 2025 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
